Table 5 End points of the CROPrEP project

1. The real-life effectiveness of daily or event-driven PrEP use:

 — HIV incidence among individuals using different PrEP regimens, compared with that of non-PrEP users randomly selected by propensity score from local expanding cohort studies of HIV-negative MSM

 — The rate of viral genotype resistance among individuals who seroconvert to HIV during the study period

2. Adherence to PrEP:

 — Number, proportion and patterns of prescribed doses taken and missed according to self—reported adherence via online questionnaires and weekly messages, reported pill use, and pill counts

 — Testing of FTC/TDF drug concentration in blood samples

 — Percentage of participants who switch regimens and their reasons

3. Safety and tolerability:

 — Rate of side effects or adverse events related to PrEP use

 — Rate of adverse events related to discontinuation of PrEP or switching PrEP regimens

4. PrEP cascade and the motivations and attitudes towards PrEP use:

 — The effectiveness of recruitment, according to the origin of roll-out

 — The cascade of PrEP use: acceptability, initiation, choice of regimen, and retention in the study

 — The knowledge, beliefs, motivations, difficulties, behavior, and expectations of participants, and their knowledge and communication regarding their PrEP use

 — Attitudes towards PrEP use and medical care providers

5. The potential effects of PrEP use on sexual behaviors and incidence of sexually transmitted infections (STIs):

 — Potential changes in the number of sexual partners and the numbers of casual or steady partners

 — Potential changes in condom use

 — Potential changes in the incidence of HSV-2 or syphilis

 — Changes in the use of sexual networks

 — Changes in perception of sexual well-being during sexual intercourse